Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:
“Excited to share our recent review in Frontiers in exploring the evolving landscape of HER2-altered non-small cell lung cancer (NSCLC).
HER2 is no longer just a breast cancer story — it’s an emerging, actionable driver in lung adenocarcinoma, particularly among never-smokers.
In this review, we cover:
- Molecular biology of HER2 mutations, amplification and overexpression
- FDA-approved diagnostics with tissue and ctDNA testing and response monitoring
- Treatment strategies including T-DXd, zongertinib, ARX788, and more
- Ongoing trials exploring ADCs, TKIs, & combination regimens.”
Title: HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities
Authors: Ahmed Ismail, Yanis Boumber, Aakash Desai
Read The Full Article at Frontiers.
More posts featuring Aakash Desai on OncoDaily.